Tag: Dr Bill Mezzanotte
CSL Limited’s AEGIS-II trial of CSL112 fails to meet primary endpoint in heart attack patients
CSL Limited (ASX:CSL; USOTC:CSLLY), a renowned global biotechnology leader, disclosed the top-line outcomes from its eagerly anticipated Phase 3 AEGIS-II trial. This pivotal study assessed ... Read More
CSL Behring bags Hemgenix EC approval for treatment of Hemophilia B
German-based biotechnology company CSL Behring has received conditional marketing authorization (CMA) from the European Commission (EC) for its Hemgenix (etranacogene dezaparvovec) indicated for the treatment ... Read More